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Background:Oneof thenitroimidazo-oxazolederivatives, IIIM-
MCD-019 discovered in-house was assessed for detailed biological
activities against various strains ofMycobacterium tuberculosis. Fur-
ther, in-vitro studies such as synergistic activity, intracellular MIC,
time kill kinetics, cell cytotoxicity, microsomal stability and phar-
macokinetics were performed. In-vivo efﬁcacy of the compound
was tested alone and in combination.
Methods & Materials: MIC was determined against H37Rv,
monoresistant as well multidrug resistant (MDR) isolates and
streptomycin starved M. tuberculosis (ss18b). Synergistic studies
were performed with rifampicin, isoniazid and ethambutol using
microdilution checkerboard assay. Time kill of the compound was
performed at MIC to 8X MIC against M. tuberculosis H37Rv. Intra-
cellular MIC was performed in macrophage J774 cell lines using
RPMI-1640 media. Cell cytotoxicity of the compound was assessed
on HepG-2 cell lines using glucose and galactose containing media
to identify mitochondrial cytotoxicity. Microsomal stability of the
compound was performed using rat liver microsomes. PK param-
eters were assessed in mice by standard protocols and In-vivo
efﬁcacy was assessed in intranasal model using Balb/c mice for 4
weeks.
Results: IIIM-MCD-019 exhibited an MIC ranged between 0.12-
0.25 g/ml for all strains except for NRP which is streptomycin
starved. When combined with rifampicin, isoniazid and ethamb-
utol individually, it showed synergistic effect with rifampicin and
isoniazid and additive effect with ethambutol and it has intracellu-
lar MIC of 1g/ml. Time kill studies shows that killing rate of this
compound is comparable to the best in class drug candidate i.e.
delamanid (OPC-67683). The compound did not exhibit cytotoxi-
city either in glucose or in galactose and found to be ≥ 99% stable
in rat liver microsomes. Pharmacokinetic proﬁle in terms of Cmax &
AUC0-t also shows1.5 times increase (Cmax of 0.54g/ml andof 7.42
g/ml* h) compared delamanid. In in-vivo model, the compound
showed 1 log reduction in cfu wrt early control and better efﬁcacy
when combined with combination of rifmapicin and isoniazid.
Conclusion: IIIM-MCD-019 is a novel compound from
nitroimidazo-oxazole scaffold and has a potent antiTB prop-
erties. The compound has shown better PK proﬁle than the drug
candidate, however further optimization of structure is required
to achieve better in-vivo efﬁcacy.
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Background: Frequently isolated in clinical settings and
environmental sources, members of the Mycobacterium avium-
intracellulare complex (MAIC) comprising genetically distinct
species and subtypes holds signiﬁcant agents responsible for
opportunistic infections. The work is focused on molecular identi-
ﬁcation of a novel Mycobacterium species within the MAIC isolated
froman aged dog suffering frompulmonary infection in a rural area
of Meghalaya, India.
Methods&Materials: The dog’s nasal swabswere collected and
after decontamination inoculated into Lowenstein Jensen Media.
Since phenotypic characteristics were inconclusive and time con-
suming, molecular analysis was decisively adopted for the study.
Genus conﬁrmation was done on the basis of hsp65 gene ampliﬁ-
cation which was then subjected to PRA (PCR-Restriction Enzyme
Pattern Analysis) using enzymes BstEII and HaeIII. To further speci-
ate the isolate anddetermine itsphylogenetic status, two important
additional housekeeping genes rpoB, and 16S rRNA gene were
included.
Results: At the end of three months a smooth, single, non-
pigmented colony was observed showing strong acid fast bacilli
and ampliﬁed the genus-speciﬁc hsp65 gene. PRA-hsp65 proﬁles
could only infer the isolate to be a Non-tuberculous Mycobacteria
(NTM). Thedogwas instantly prescribed anti-tuberculosis drug and
is currently undergoing therapy. BLAST analysis in NCBI exhibited
no homology in the three genes with comparatively low similarity
cut-offs. The 16S rRNAgenedepicted 99% closeness to the reference
strain ofM. yongonense, rpoB gene showed 97% similarity toM. Indi-
cus pranii, while non-MAIC member M. genevense was the closest
hit for hsp65 with 97% similarity. All the three genes were individ-
ually subjected to phylogenetic analysis in MEGA6 taking together
the reference ATCC sequences of MAIC and the closest BLAST hits
which also presented similar ambiguous outputwith no conclusion
on the isolate’s species. Concatenation of the three sequences ulti-
mately presented higher lucid discrimination and determined the
isolate (HNP-1) as a novel entity within the MAIC (Figure 1).
